RxDoctor Payments DataLook up a doctor →

Carmen Canals-Navas, MD

Nephrology · Voorhees, NJNPI 1144277518

Payments from drug & device makers

$11,519in general payments, 2019–2025

Across 554 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$1K
  • Fresenius USA Marketing, Inc.$1K
  • AstraZeneca$1K
  • Bayer$949
  • Akebia Therapeutics Inc$826
  • Bard Peripheral Vascular, Inc.$771
  • plus $5K from 33 others

What the payments were for

  • Speaking & faculty fees$2002%
  • Food & beverage$11,20197%
  • Education$1181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,519 in reported general payments places this provider in the 90th percentile of 413 nephrology providers in New Jersey.

See all nephrology providers in New Jersey

Medicare billing

Part B allowed, 2024
$380,770
Medicare patients
506
Services billed
1,997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide43$175,284
FarxigaDapagliflozin Propanediol193$169,167
XphozahTenapanor Hcl28$81,562
Lanthanum Carbonate49$61,256
AuryxiaFerric Citrate26$57,791
KerendiaFinerenone43$40,245
EliquisApixaban34$37,496
VeltassaPatiromer Calcium Sorbitex32$34,065
IsentressRaltegravir Potassium13$29,596
LokelmaSodium Zirconium Cyclosilicate25$25,665
Sevelamer Carbonate107$19,534
Etravirine13$16,380
Hydralazine Hcl215$3,629
Cinacalcet Hcl11$3,450
Potassium Chloride35$2,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,229$194,832218 claims
Fresenius USA Marketing, Inc.Velphoro$1,309$175,28443 claims
Akebia Therapeutics IncAuryxia$826$57,79126 claims
BayerKerendia$949$40,24543 claims
ANI Pharmaceuticals, Inc.Valsartan$436$73129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 413 nephrology providers in New Jersey.

Other nephrology in Voorhees

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →